Aug 5, 2025 08:01AM
Aug 5, 2025 08:00AM
May 27, 2025 08:00AM
May 15, 2025 08:00AM
May 5, 2025 08:00AM
Apr 29, 2025 08:00AM
Jul 11, 2024 06:40PM Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Jun 2, 2024 08:56PM
Jun 2, 2024 08:38PM
Aug 1, 2023 08:00AM
Jul 31, 2023 08:00AM
Jul 31, 2023 08:00AM
Jul 28, 2023 08:00AM
Jun 27, 2023 08:00AM Immutep Secures Third United States Patent for Eftilagimod Alpha in Combination with a PD-1 Pathway Inhibitor
Jun 5, 2023 08:00AM
May 26, 2023 08:00AM
May 25, 2023 08:00AM
May 24, 2023 08:00AM
May 16, 2023 08:00AM
May 2, 2023 08:00AM
May 1, 2023 08:00AM Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
Apr 27, 2023 08:00AM
Apr 17, 2023 09:00AM
Mar 31, 2023 08:01AM
Mar 31, 2023 08:00AM
Mar 30, 2023 08:00AM
Mar 14, 2023 08:00AM
Jan 30, 2023 08:00AM Immutep Quarterly Activities Report
Jan 4, 2023 08:00AM
Dec 23, 2022 08:00AM
Dec 8, 2022 08:00AM
Nov 29, 2022 08:00AM
Nov 10, 2022 11:11AM
Nov 10, 2022 11:10AM
Nov 10, 2022 09:00AM Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
Nov 9, 2022 08:00AM
Nov 4, 2022 08:00AM
Nov 2, 2022 08:00AM
Oct 26, 2022 08:00AM
Oct 25, 2022 08:00AM
Oct 4, 2022 08:00AM
Sep 14, 2022 08:00AM Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Aug 1, 2022 08:00AM
Jul 28, 2022 08:00AM
Jul 6, 2022 08:00AM
May 18, 2022 08:00AM
Apr 29, 2022 08:00AM
Mar 10, 2022 08:00AM
Jan 25, 2022 08:00AM Immutep Quarterly Activities Report
Nov 15, 2021 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All